Roxanne Lagano Sells 923 Shares of Zoetis Inc. (NYSE:ZTS) Stock

Zoetis Inc. (NYSE:ZTSGet Free Report) EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Friday, November 17th. The shares were sold at an average price of $177.46, for a total transaction of $163,795.58. Following the completion of the sale, the executive vice president now directly owns 22,665 shares of the company’s stock, valued at approximately $4,022,130.90. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Roxanne Lagano also recently made the following trade(s):

  • On Wednesday, October 18th, Roxanne Lagano sold 923 shares of Zoetis stock. The shares were sold at an average price of $172.92, for a total transaction of $159,605.16.
  • On Monday, September 18th, Roxanne Lagano sold 923 shares of Zoetis stock. The shares were sold at an average price of $179.58, for a total value of $165,752.34.
  • On Friday, September 1st, Roxanne Lagano sold 923 shares of Zoetis stock. The shares were sold at an average price of $192.97, for a total value of $178,111.31.

Zoetis Price Performance

Shares of Zoetis stock traded up $1.26 during trading on Monday, hitting $176.06. 1,056,233 shares of the stock traded hands, compared to its average volume of 1,973,395. The firm’s fifty day moving average is $171.85 and its 200-day moving average is $175.65. The stock has a market cap of $80.83 billion, a price-to-earnings ratio of 35.53, a PEG ratio of 2.85 and a beta of 0.83. Zoetis Inc. has a 52 week low of $140.76 and a 52 week high of $194.99. The company has a quick ratio of 2.16, a current ratio of 3.87 and a debt-to-equity ratio of 1.29.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Wednesday, November 1st will be issued a $0.375 dividend. The ex-dividend date of this dividend is Tuesday, October 31st. This represents a $1.50 dividend on an annualized basis and a dividend yield of 0.85%. Zoetis’s payout ratio is 30.49%.

Hedge Funds Weigh In On Zoetis

Several institutional investors and hedge funds have recently made changes to their positions in ZTS. Quantinno Capital Management LP boosted its position in Zoetis by 2.6% during the second quarter. Quantinno Capital Management LP now owns 18,431 shares of the company’s stock valued at $3,174,000 after buying an additional 475 shares during the period. Artisan Partners Limited Partnership bought a new position in Zoetis during the 1st quarter worth approximately $16,589,000. FirstPurpose Wealth LLC increased its stake in Zoetis by 3.7% in the 2nd quarter. FirstPurpose Wealth LLC now owns 2,126 shares of the company’s stock worth $366,000 after purchasing an additional 75 shares during the period. FORVIS Wealth Advisors LLC boosted its stake in shares of Zoetis by 4.7% during the second quarter. FORVIS Wealth Advisors LLC now owns 1,350 shares of the company’s stock valued at $232,000 after purchasing an additional 61 shares during the period. Finally, Arcataur Capital Management LLC purchased a new position in shares of Zoetis in the second quarter worth $442,000. Institutional investors own 89.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ZTS. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 8th. The Goldman Sachs Group raised their price objective on shares of Zoetis from $204.00 to $213.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. Piper Sandler boosted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, November 6th. Argus increased their price objective on Zoetis from $190.00 to $201.00 in a research report on Tuesday, September 19th. Finally, Stifel Nicolaus reduced their target price on Zoetis from $205.00 to $195.00 and set a “buy” rating for the company in a research report on Monday, October 30th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $216.29.

Check Out Our Latest Stock Report on ZTS

About Zoetis

(Get Free Report)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Insider Buying and Selling by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.